After 6 years with Xolair; a 3-year withdrawal follow-up
| Autor: | Anna, Nopp, S G O, Johansson, J, Adédoyin, J, Ankerst, M, Palmqvist, H, Oman |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Clinical Trials as Topic Antibodies Monoclonal Omalizumab Allergens Immunoglobulin E Middle Aged Antibodies Monoclonal Humanized Asthma Antibodies Anti-Idiotypic Basophils Forced Expiratory Volume Surveys and Questionnaires Cats Hypersensitivity Animals Humans Anti-Asthmatic Agents Aged Follow-Up Studies |
| Zdroj: | Allergy. 65(1) |
| ISSN: | 1398-9995 |
| Popis: | This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma.The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV(1) and a questionnaire.Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels.Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text